Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement
source: shutterstock.com

Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement

According to reporting from Healio Psoriatic Disease, the Food and Drug Administration (FDA) recently updated the label for Dupixent (dupilumab) in the indication of moderate-to-severe atopic dermatitis with moderate-to-severe hand…

Continue Reading Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement
HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission
source: pixabay.com

HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission

In January 2024, the FDA approved Hyqvia (Immune Globulin Infusion 10% [Human]) as a maintenance therapy for adults living with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder.  As…

Continue Reading HYQVIA and ENHANZE Co-Formulation Approved as Maintenance Therapy for CIDP by European Commission